Loading stock data…
Ligand Pharmaceuticals Incorporated (LGND)
$300.53-1.62 (-0.54%)
Market ClosedLast close Jul 24
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ligand Pharmaceuticals Incorporated in the Healthcare sector is trading at $300.53 with a market capitalization of $5.1B. Wall Street consensus targets $323.30 (10 analysts), implying a +7.6% move over the next 12 months. The stock is currently near its 52-week high of $326.63, remaining 38.2% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +7.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $51.72M↓ | $59.67M↓ | $115.46M↑ | $47.63M↑ | $45.33M |
| Gross Profit | $48.45M↓ | $56.67M↓ | $111.66M↑ | $44.72M↑ | $40.48M |
| Operating Income | $17.37M↓ | $20.04M↓ | $54.10M↑ | $9.72M↑ | -$36.66M |
| Net Income | -$13.35M↓ | $44.78M↓ | $117.27M↑ | $4.85M↑ | -$42.45M |
Peer Comparison
JNJUNHPFE
Fundamentals
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.09B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
15.40%
Volume
Today's trading volume
246,723
Recent News
Shopify downgraded, Five Below upgraded: Wall Street's top analyst calls
Shopify downgraded, Five Below upgraded: Wall Street's top analyst calls
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Adobe, Datadog, Five Below, Fortinet, Gilead Sciences, Goldman Sachs, Microsoft, Salesforce, and More
Wall Street analysts are making bold moves on Tuesday, shaking up ratings for some of the biggest names in tech, biotech, and retail in ways that could catch investors off guard. Find out which stocks got slashed and which ones earned surprise upgrades.
Ligand Pharmaceuticals (LGND) Stock Looks Undervalued On Cash Flow Yet Overvalued On Earnings
Ligand Pharmaceuticals stock has delivered a very large 338.7% return over the past three years, yet its valuation signals are split, with an intrinsic value estimate from a Discounted Cash Flow (DCF) model suggesting the shares trade below that estimate while market multiples and a low overall value score point to a richer pricing. The 338.7% three year return puts a spotlight on whether the current price already embeds much of the good news in Ligand Pharmaceuticals. The completed US$739m...
AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot
Agenus surges after securing up to $340M in financing to fund its phase III ROBBIN colon cancer study and extend its cash runway if warrants are exercised.
Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last?
Agenus (AGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.